Gene Logic Expands ToxExpress Solutions - Launches New Molecular Mechanism of Toxicity Services

New Services Complement Expanding ToxExpress Solutions for Predictive Toxicogenomics

13-Mar-2003

Gene Logic Inc. announced the expansion of its ToxExpress toxicogenomics solutions with the launch of its Molecular Mechanism of toxicity (ToxMOT) services. This new service, as well as the other products and services within Gene Logic's state-of-the-art toxicogenomics program, will be discussed in various forums at the Society of toxicology (SOT) Annual Meeting for 2003.

Gene Logic's ToxExpress Solutions consists of a broad range of gene expression-based products and services that provide a comprehensive and flexible approach to toxicogenomic analysis. The new ToxMOT Services build on the Company's recognized expertise in toxicogenomics and offer researchers a new, solution-oriented analysis service for unraveling and understanding mechanism of toxicity as it relates to drug development.

Gene Logic will conduct studies on customers' specific candidate drugs to determine the "how" and "why" of observed or anticipated toxicity in each compound under analysis. The ToxMOT Services can augment current research efforts spanning the lead optimization through the early clinical phases of development. These services offer Gene Logic's pharmaceutical and biotechnology customers critical insights into the toxic potential of their lead compounds. Specifically, these services will enable researchers to: 1) determine molecular mechanisms being triggered by toxicity; 2) understand biological changes following adverse events; 3) confirm observations or suspicions of toxicity; and 4) facilitate drug development decisions through ranking of compounds based on their mechanism of toxicity.

ToxMOT Services are currently available, under contract agreement, for fees determined by the scope and complexity of the analysis to be conducted.

Commenting on this new service offering, Donna Mendrick, Ph.D., Vice President and Scientific Director for Toxicogenomics at Gene Logic, said, "The launch of our ToxMOT Services is a continuation of our commitment to expand the application of toxicogenomics into the mainstream drug development process.

The objective of our toxicogenomics approach is to enable our customers to better understand and predict human toxicity at an earlier stage, resulting in lower failure rates in the preclinical and early clinical phases of development."

https://www.bionity.com/en/news/21259/gene-logic-expands-toxexpress-solutions-launches-new-molecular-mechanism-of-toxicity-services.html